Dr. Jeroen Mertens, Nucleaire Geneeskunde
0704.757.557 · rovalta.com · 28/09/2026
ACTIVE
Dr. Jeroen Mertens, Nucleaire Geneeskunde
Financial year 2025 · Closed on 31/12/2025
Net result455,4 k €+1,0 %over 1 year
Gross margin597,3 k €-2,6 %over 1 year
Equity225,3 k €-0,3 %over 1 year
Overview
Identity
Source · BCE/KBODr. Jeroen Mertens, Nucleaire Geneeskunde is a Private limited company incorporated in 2018. Its main activity is: Specialist medical practice activities. Its registered office is in Gent.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0704.757.557
- Incorporation
- 19/09/2018
- Legal form
- Private limited company
- Registered office
- Lange Violettestraat 211
9000 Gent · FlandreSee on map - Contributed capital
- 18 600,00 €
- Latest accounts
- 31/12/2025
Activities (NACE)
Signals
ProfitableLow riskGood liquidityPositive cashflowPositive EBITDA
Financials
Source · NBB, 8 filingsTrend over 5 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 597,3 k € | -2.6% | 613,3 k € | +28.3% | 477,9 k € | +10.7% | 431,8 k € | -1.5% | 438,3 k € |
| EBITDA | 596,3 k € | -2.5% | 611,8 k € | +28.5% | 476,2 k € | +10.7% | 430 k € | -1.4% | 436 k € |
| Operating result | 585,6 k € | -2.6% | 601,4 k € | +28.8% | 466,8 k € | +10.5% | 422,6 k € | -1.6% | 429,4 k € |
| Net result | 455,4 k € | +1.0% | 450,8 k € | +26.2% | 357,3 k € | +11.7% | 319,9 k € | -1.9% | 325,9 k € |
| Balance sheet | |||||||||
| Equity | 225,3 k € | -0.3% | 225,9 k € | -25.8% | 304,2 k € | +0.1% | 303,9 k € | -0.4% | 305,1 k € |
| Total assets | 951,7 k € | +11.6% | 852,7 k € | +15.2% | 740,4 k € | +7.5% | 688,5 k € | -2.2% | 704,1 k € |
| Cash | 704,6 k € | +37.4% | 512,7 k € | +49.2% | 343,6 k € | -2.5% | 352,5 k € | +8.3% | 325,6 k € |
| Debts | 714,4 k € | +15.4% | 619 k € | +41.9% | 436,2 k € | +13.4% | 384,6 k € | -3.6% | 399,1 k € |
Valuation
Indicative valuation
As an indication, this company is worth
between 2,5 M€ and 5 M€
See the valuationBoard of directors
Source · NBB, accounts to 31/12/20251 active
Active mandates
| Director | Mandates in this company | Period |
|---|---|---|
Jeroen Mertens | Directorsince 17/09/2018Managersince 19/09/2018ended |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Micro model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 10/07/2026 | 22/07/2025 | 18/04/2024 | 04/07/2023 | 17/10/2022 | 03/06/2021 |
| General meeting | 25/06/2026 | 14/07/2025 | 29/03/2024 | 06/06/2023 | 10/10/2022 | 01/06/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 8 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 25/06/2026 | 10/07/2026 | Dutch | |
| Abridged model | 31/12/2024 | 14/07/2025 | 22/07/2025 | Dutch | |
| Abridged model | 31/12/2023 | 29/03/2024 | 18/04/2024 | Dutch | |
| Abridged model | 31/12/2022 | 06/06/2023 | 04/07/2023 | Dutch | |
| Abridged model | 31/12/2021 | 10/10/2022 | 17/10/2022 | Dutch | |
| Micro model | 31/12/2020 | 01/06/2021 | 03/06/2021 | Dutch | |
| Micro model | 31/12/2019 | 02/06/2020 | 03/06/2020 | Dutch | |
| Micro model | 31/12/2018 | 04/06/2019 | 29/07/2019 | Dutch |
Valuation
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 2,5 M€ and 5 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20251 active
Active mandates
| Director | Mandates in this company | Period |
|---|---|---|
Jeroen Mertens | Directorsince 17/09/2018Managersince 19/09/2018ended |
Ownership and network
Looking for more information about this company?
Try for freePublications
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
Source · CBE, NBB annual accountsYear
Identity
Incorporation
Name
Registered office
Annual accounts
Filings5 filings
Mandates
Jeroen Mertens
201820192020202120222023202420252026
Dr. Jeroen Mertens, Nucleaire Geneeskunde
Lange Violettestraat 211, 9000 GentHof Resselaar 25, 9820 Merelbeke-Melle
Director
CurrentPlanned, not yet servedEndedAccounts filedToday
Registered offices
Source · NBB annual accounts, CBE| Registered address | Period | Source |
|---|---|---|
| Lange Violettestraat 211, 9000 GentCurrent | accounts 2023 → 2025 | Accounts 2025 · 2026-00278464 |
| Hof Resselaar 25, 9820 Merelbeke-Melle | accounts 2021 → 2022 | Accounts 2022 · 2023-00206930 |
Company names
Source · NBB annual accounts, CBE| Name | Period | Source |
|---|---|---|
| Dr. Jeroen Mertens, Nucleaire GeneeskundeCurrent | accounts 2018 → 2025 | Accounts 2025 · 2026-00278464 |
Events
- 2025Annual accounts 2025455,4 k €↑
- 2024Annual accounts 2024450,8 k €↑
- 2023Annual accounts 2023357,3 k €↑
- 2022Annual accounts 2022319,9 k €↓
- 2021Annual accounts 2021325,9 k €
- 19/09/2018IncorporationPrivate limited company